Fairview Capital Investment Management LLC Has $746,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Fairview Capital Investment Management LLC trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 80.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,063 shares of the medical equipment provider's stock after selling 28,779 shares during the period. Fairview Capital Investment Management LLC's holdings in Zimmer Biomet were worth $746,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at approximately $25,000. Accredited Wealth Management LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at approximately $36,000. Kentucky Trust Co purchased a new position in Zimmer Biomet in the fourth quarter valued at approximately $39,000. OFI Invest Asset Management purchased a new position in Zimmer Biomet in the fourth quarter valued at approximately $40,000. Finally, Dunhill Financial LLC increased its stake in Zimmer Biomet by 86.6% in the fourth quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 206 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.39% of the company's stock.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH traded up $0.11 during trading on Friday, hitting $95.22. 3,438,566 shares of the stock were exchanged, compared to its average volume of 1,722,258. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.92 and a 1-year high of $122.25. The company has a market capitalization of $18.84 billion, a price-to-earnings ratio of 21.40, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The company's fifty day simple moving average is $104.43 and its 200-day simple moving average is $106.13. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet's revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the company earned $1.94 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were given a $0.24 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.01%. Zimmer Biomet's payout ratio is 21.24%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a "buy" rating in a report on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Robert W. Baird decreased their price target on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Royal Bank of Canada decreased their price target on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Finally, Barclays decreased their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $114.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.